Analysts Expect Corium International Inc (CORI) Will Post Earnings of -$0.39 Per Share

Analysts expect that Corium International Inc (NASDAQ:CORI) will post earnings of ($0.39) per share for the current quarter, according to Zacks. Two analysts have provided estimates for Corium International’s earnings. The lowest EPS estimate is ($0.44) and the highest is ($0.33). Corium International reported earnings of ($0.43) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 9.3%. The business is scheduled to issue its next earnings report on Thursday, August 2nd.

On average, analysts expect that Corium International will report full-year earnings of ($1.59) per share for the current fiscal year, with EPS estimates ranging from ($1.73) to ($1.50). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.46) per share, with EPS estimates ranging from ($1.74) to ($1.09). Zacks’ earnings per share averages are an average based on a survey of analysts that that provide coverage for Corium International.

Corium International (NASDAQ:CORI) last released its quarterly earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). Corium International had a negative net margin of 156.05% and a negative return on equity of 273.01%. The company had revenue of $10.06 million during the quarter, compared to analyst estimates of $7.07 million.

A number of equities research analysts recently issued reports on the stock. BidaskClub raised shares of Corium International from a “strong sell” rating to a “sell” rating in a research note on Wednesday, June 13th. Zacks Investment Research cut shares of Corium International from a “buy” rating to a “hold” rating in a research note on Thursday, April 5th. ValuEngine raised shares of Corium International from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 price target on shares of Corium International in a research note on Friday, May 18th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. Corium International currently has a consensus rating of “Buy” and an average price target of $13.00.

Corium International opened at $8.90 on Friday, MarketBeat reports. Corium International has a 1 year low of $6.97 and a 1 year high of $13.93. The firm has a market capitalization of $320.02 million, a P/E ratio of -5.43 and a beta of 1.54. The company has a debt-to-equity ratio of 1.89, a quick ratio of 7.95 and a current ratio of 8.11.

A number of hedge funds have recently made changes to their positions in the business. Iguana Healthcare Management LLC lifted its holdings in Corium International by 22.2% in the 1st quarter. Iguana Healthcare Management LLC now owns 110,000 shares of the biopharmaceutical company’s stock valued at $1,262,000 after purchasing an additional 20,000 shares in the last quarter. Citadel Advisors LLC purchased a new position in Corium International in the 1st quarter valued at $455,000. Franklin Resources Inc. lifted its holdings in Corium International by 115.3% in the 1st quarter. Franklin Resources Inc. now owns 2,059,175 shares of the biopharmaceutical company’s stock valued at $23,618,000 after purchasing an additional 1,102,910 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Corium International by 1,746.7% in the 1st quarter. JPMorgan Chase & Co. now owns 96,935 shares of the biopharmaceutical company’s stock valued at $1,112,000 after purchasing an additional 91,686 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its holdings in Corium International by 127.9% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 196,000 shares of the biopharmaceutical company’s stock valued at $2,248,000 after purchasing an additional 110,000 shares in the last quarter. Institutional investors own 94.79% of the company’s stock.

About Corium International

Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.

Get a free copy of the Zacks research report on Corium International (CORI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply